Vozmozhnosti obespecheniya nefroprotektsii na fone blokady retseptorov angiotenzina II kandesartanom u bol'nykh arterial'noy gipertoniey

Vozmozhnosti obespecheniya nefroprotektsii na fone blokady retseptorov angiotenzina II kandesartanom u bol'nykh arterial'noy gipertoniey

Исследование почечной гемодинамики у больных артериальной (эссенциальной) гипертонией (АГ) свидетельствует о том, что по мере прогрессирования заболевания нарастает почечное сосудистое сопротивление и как следствие уменьшается почечный кровоток, тогда как клубочковая фильтрация часто поддерживается...

Full description

Bibliographic Details
Main Authors:	N M Chikhladze, I E Chazova
Format:	Article
Language:	Russian
Published:	IP Morozov P.V. 2004-03-01
Series:	Системные гипертензии
Subjects:	артериальная гипертония нефропротекция блокаторы рецепторов ангиотензина кандесартан
Online Access:	https://syst-hypertension.ru/2075-082X/article/view/28705

Similar Items

Novoe pokolenie blokatorov retseptorov angiotenzina
by: Valeriy Ivanovich Podzolkov, et al.
Published: (2013-09-01)

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015-12-01)

Farmakologicheskaya blokada angiotenzinovykh retseptorov v lechenii arterial'noy gipertenzii: ot saralazina do sartanov
by: Viktor Viktorovich Fomin, et al.
Published: (2013-09-01)

POSSIBILITY OF ANGIOTENSIN RECEPTOR BLOCKERS IN OPTIMIZING OF ANTIHYPERTENSIVE PHARMACOTHERAPY IN PATIENTS AFTER STROK
by: Z M. Sizova
Published: (2015-09-01)

A META-ANALYSIS REPORTING EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTSWITHOUT HEART FAILURE
by: G. Savarese, et al.
Published: (2015-09-01)

Clinical efficacy of AT1-receptors of angiotensin II valsartan in the pharmacotherapy of patients with arterial hypertension and chronic heart failure
by: A K Starodubtsev, et al.
Published: (2010-12-01)

Angiotensin II receptor blockers and cardiorenal risk management: Irbesartan status
by: V. V. Fomin
Published: (2013-12-01)

Comparison of registration parameters of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in different countries
by: A F Garaeva, et al.
Published: (2018-08-01)

Blokatory retseptorov k angiotenzinu II v lechenii diabeticheskoy nefropatii s pozitsiy dokazatel'noy meditsiny
by: M V Shestakova
Published: (2006-03-01)

Cardiometabolic properties of telmisartan: new perspectives for use
by: O. M. Drapkina, et al.
Published: (2015-12-01)

ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT
by: S. Yu. Martsevich
Published: (2015-09-01)

Current approach to antihypertensive therapy
by: M. V. Kuznetsova
Published: (2015-12-01)

FREE-RADICAL OXIDATION ACTIVITY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITHOUT Q WAVE TREATED WITH EPROSARTAN OR ENALAPRIL ADDITIONALLY TO THE BASIC THERAPY
by: O. G. Zaylobidinov, et al.
Published: (2016-01-01)

The choice of combination antihypertensive therapy in patients with type 2 diabetes
by: O. A. Koshelskaya, et al.
Published: (2015-12-01)

IRBESARTAN IN THE CLINICAL PRACTICE
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

Mesto agonistov imidazolinovykh retseptorov v lechenii arterial'noy gipertenzii: rezul'taty issledovaniya MERSY v Rossii
by: Irina Evgen'evna Chazova, et al.
Published: (2009-09-01)

Blokatory retseptorov angiotenzina II pri lechenii arterial'noy gipertonii
by: L I Ol'binskaya
Published: (2005-06-01)

Sravnenie nefroprotektivnykh effektov selektivnogo blokatora endotelinovykh retseptorov i ingibitora APF na modeli eksperimental'nogo sakharnogo diabeta tipa 2
by: E Fedorova, et al.
Published: (2004-03-01)

Sakharnyy diabet i arterial'naya gipertoniya: kakovy preparaty pervogo ryada vybora?
by: M V Shestakova
Published: (2005-03-01)

Terapiya irbesartanom bol'nykh sakharnym diabetom tipa 2: metabolicheskie effekty i vliyanie na perfuziyu golovnogo mozga
by: K M Mamyrbaeva, et al.
Published: (2006-06-01)

THE EFFICACY OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANTAGONISTS OF THE RECEPTORS OF THE 1ST TYPE OF ANGIOTENSIN II IN PATIENTS WITH CORONARY ARTERY DISEASE POSTINFARCTION CARDIOSCLEROSIS COMBINED WITH DIABETES MELLITUS TYPE 2 AND ARTERIAL HYPERTENSION
by: Zarina Vyacheslavovna Bitarovа, et al.
Published: (2016-07-01)

Effect of long-term therapy with AT1angiotensin II receptor blockers in combination with aldosterone receptor inhibitor on ischemic myocardial remodelling and chronic heart failure
by: AT Teplyakov, et al.
Published: (2014-12-01)

Kardioi nefroprotektivnye effekty agonista imidazolinovykh retseptorov moksonidina v lechenii arterial'noy gipertenzii u bol'nykh sakharnym diabetom 2 tipa
by: Alexander Sergeevich Ametov, et al.
Published: (2004-12-01)

Lechenie patsienta s arterial'noy gipertenziey i gipertrofiey levogo zheludochka
by: I E Chazova, et al.
Published: (2006-03-01)

Blokatory retseptorov angiotenzina II pokazany bol'shinstvu bol'nykh arterial'noy gipertenziey?
by: V V Fomin
Published: (2008-03-01)

Kardioprotektivnye svoystva blokatorov retseptorov angiotenzina II: fokus na lozartan
by: T E Morozova, et al.
Published: (2010-06-01)

Vozmozhnosti primeneniya beta-adrenoblokatorov s vazodilatiruyushchimi svoystvami u bol'nykh arterial'noy gipertoniey
by: N M Chikhladze, et al.
Published: (2004-06-01)

Nefroprotektivnyy effekt antigipertenzivnoy terapii: issledovanie IRIS
by: L G Ratova, et al.
Published: (2004-06-01)

Effektivnost' vozdeystviya blokatora AT1-angiotenzinovykh retseptorov irbesartana na organy-misheni u bol'nykh arterial'noy gipertoniey
by: N M Chikhladze, et al.
Published: (2004-06-01)

Treatment of insomnia in neurologist's practice
by: N. V. Pizova
Published: (2014-12-01)

Kognitivnye narusheniya u bol'nykh s arterial'noy gipertoniey: novye dannye o vozmozhnosti ikh uluchsheniya na fone lecheniya eprosartanom
by: O D Ostroumova, et al.
Published: (2010-09-01)

Blokatory kal'tsievykh kanalov III pokoleniya pri lechenii arterial'noy gipertonii
by: Aleksandr Mikhaylovich Shilov
Published: (2013-09-01)

INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION
by: K. B. Mirzaev, et al.
Published: (2015-09-01)

Olmesartan: vasoprotective effects and reducing the risk of vascular accidents
by: O. D. Ostroumova, et al.
Published: (2014-12-01)

Angiotensin II receptor antagonist valsartan in treatment of patients with arterial hypertension and chronic kidney diseases. Hypotensive and nephroprotective efficacy
by: M L Maximov, et al.
Published: (2010-09-01)

Clinical efficiency of medium and high doses of valsartan in the treatment of patient with arterial hypertension and chronic kidney diseases
by: M L Maximov, et al.
Published: (2010-12-01)

Pharmacoeconomic analysis of the use of ramipril and candesartan in patients with arterial hypertension
by: Alena Marushchak, et al.
Published: (2018-06-01)

NEW ANTIPLATELET DRUGS (PART 1)
by: A. B. Sumarokov
Published: (2016-01-01)

Clinical pharmacology of angiotensin II receptor blockers: valsartan
by: M. V. Leonova
Published: (2014-12-01)

Depression and insomnia in patients with CAD
by: E. S. Akarachkova, et al.
Published: (2014-12-01)